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Background
Shortly after their discovery in 1957 [1-3], antibodies to 
dsDNA were associated with renal manifestation of 
systemic lupus erythematosus (SLE). A prominent obser-
vation was that anti-dsDNA antibodies were eluted from 
aﬀ  ected glomeruli in the context of lupus nephritis [4-8]. 
At the time when the nephritogenic potential of anti-
bodies to dsDNA was revealed, their binding in glomeruli 
was logically claimed to depend on exposed DNA. Th  is 
DNA was thought to be bound in situ in glomeruli, where 
it was targeted by the antibodies. Th  is assumption 
derived from two facts: DNA bound glomerular collagen 
[9,10], and the antibodies were speciﬁ  c for DNA [11,12].
One problem was linked with this model. Not all 
individuals with anti-dsDNA antibodies in their circu  la-
tion developed nephritis. A convenient model to under-
stand nephritogenicity of anti-dsDNA antibodies 
proposes that only those antibodies which cross-reacted 
with inherent renal antigens induced the organ disease. A 
nephritogenic potential of antibodies against DNA (or 
nucleosomes) is thus today critically challenged by alter-
native models implying that antibodies cross-react with 
glomerular antigens such as α-actinin, laminin, or cell 
surface structures [13-19]. Conﬂ  icting data from diﬀ  erent 
types of analytical strategies have resulted in diﬀ  erent 
models explaining how anti-DNA antibodies induce 
nephritis. Even though these models are attractive, none 
have been validated beyond any doubt, although the 
domi nant  speciﬁ   city of nephritogenic antibodies for 
dsDNA may point to the most obvious target structures 
in nephritic kidneys – nucleosomes released from dead 
cells. An alternative model that may explain whether an 
anti-dsDNA antibody executes a nephritogenic potential 
might therefore be the availability of exposed chromatin 
particles within glomeruli. Th  is hypothesis means that 
anti-dsDNA antibodies execute their pathogenic poten-
tial only in situa  tions where chromatin fragments are 
exposed in glomeruli. In the absence of this target 
structure, the antibodies remain nonpathogenic epi-
phenomena despite their diagnostic potential.
Th   e origin of renally exposed chromatin fragments has 
been diﬃ   cult to assess. One general idea has been that 
they reach glomeruli through circulation. Taking into 
consideration that the target antigens for anti-dsDNA 
and anti-nucleosome antibodies appear by immune elec-
tron microscopy as large chromatin fragments [20], how-
ever, it is diﬃ   cult to explain how these may reach and 
deposit in glomeruli.
A notable change in thinking entailed by our studies is 
rather that chromatin fragments exposed in glomeruli 
are released from dying renal cells, and that these frag-
ments are not degraded during the cell death process 
because of an acquired loss of the dominant renal 
nuclease DNaseI [21]. Th  is model is the focus of the 
present review, and will be discussed in detail below.
Nephritis in systemic lupus erythematosus
SLE, as we understand the disease today, is linked to B-cell 
and T-cell autoimmunity to nucleosomes, and particularly 
to the individual components of nucleosomes  – native 
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parameters for SLE [12,22]. Furthermore, sets of these 
autoantibodies possess the potential to induce nephritis, 
the most serious complication in SLE [23,24].
Th   e aetiology of SLE is not fully understood, but there 
are recent advances in its understanding. For example, 
there is growing interest in regulatory RNA molecules in 
SLE. miRNAs belong to a family of short noncoding 
RNAs. Th   ese have been shown to play important roles in 
gene regulation. Recent data suggest that miR-126 regu-
lates DNA methylation in CD4+ T cells and contributes 
to T-cell autoreactivity in SLE by directly targeting 
DNMT1 [25]. Similarly, a recently published compre  hen-
sive analysis of miRNA expression patterns in renal 
biopsies of lupus nephritis patients further demonstrates 
that miRNAs are probable factors involved in the patho-
genesis of lupus nephritis. We see now the contour of a 
new scientiﬁ  c  ﬁ   eld to understand elements of lupus 
nephritis; study of regulatory RNA in autoimmune 
syndromes such as SLE and lupus nephritis is a new and 
fast-growing ﬁ  eld to analyse transcriptomics in SLE [26], 
and miRNA may have a strong impact on progressive 
kidney diseases as discussed by Kato and colleagues [27].
Another cascade of events that may relate to patho-
genesis of SLE and lupus nephritis is linked to engage-
ment of Toll-like receptors (TLRs) by exposed chromatin. 
Activation of TLRs induces upregulation of proinﬂ  amma-
tory cytokines (TNFα, IFNγ) and interleukins [28]. For 
example, IFNγ contributes directly to the progression of 
lupus nephritis [29]. Furthermore, Rönnblom and 
colleagues discussed recently the increasing evidence 
that activated type I interferons in lupus are critical in the 
aetiopathogenesis of the disease and an important 
therapeutic target [30]. Kidney sections from patients 
with SLE glomerulonephritis contain high amounts of 
TNFα, and expression levels correlated with local 
(histological) disease activity [31].
TNFα and IFNγ are important inducers of the matrix 
metalloproteases (MMPs) MMP2 and MMP9. Th  ese  are 
collagenases that, when overexpressed, have the potential 
to disintegrate membranes [32,33]. Membrane disinte-
gra  tion may be the factor that promotes deposition of 
immune complexes in glomerular basement membranes 
(GBMs), as discussed recently [34]. Th  e engagement of 
TLRs is thus an event central in the pathogenesis and 
progression of SLE and lupus nephritis.
In the next sections, the current insight into murine 
forms of lupus nephritis will be discussed, with potential 
implications of data on the human form of this organ 
disease.
Murine lupus nephritis
Substantial data have been provided during recent years 
related to why and how anti-dsDNA antibodies are 
produced (see, for example, [35-39]); to how they exert 
their clinical impact, whether through interaction with 
DNA or nucleosomes [5,40-42], or through cross-reac-
tion with inherent renal antigens [13,15,17,43]; and to 
analyse whether the nature of their glomerular target 
structures are reﬂ   ected by their speciﬁ   city or cross-
reactivity [12,40,44].
Glomerular target structures for nephritogenic 
autoantibodies
In recent studies, we and other workers have developed 
high-resolution techniques providing evidence that 
nephrito  genic anti-dsDNA/nucleosome antibodies recog-
nise selectively intraglomerular, extracellular chromatin 
structures in vivo [20,40,41,44]. Th   ese structures appear 
as electron-dense structures by transmission electron 
microscopy, and have been shown to be composed of 
chromatin fragments and IgG molecules by diﬀ  erent 
forms of immune electron microscopy and by co-locali-
sation terminal deoxynucleotidyltransferase biotin-dUTP 
nicked end-labelled immune electron microscopy assay 
[20]. Autoantibody deposits in vivo are strictly localised 
to these structures, and co-localise with antibodies to 
DNA and histones added to the sections in vitro [20].
Th   ese data conﬁ  rm the historical hypothesis that anti-
dsDNA antibodies form complexes with nucleosomes 
and these immune complexes deposit in glomerular 
mem  branes (reviewed in [44]). Th   is deposition does not 
exclude the involvement of other autoantibodies that may 
participate in the progression of lupus nephritis, such as 
antibodies speciﬁ  c for the membrane and matrix compo-
nent [6], α-actinin [13,43], C1q [45] and, for example, 
renal cell membranes [46]. Th   e role of these latter anti-
bodies in lupus nephritis, however, remains to be 
deter mined.
Central role of renal DNaseI, chromatin fragments, 
anti-dsDNA antibodies, and matrix metalloproteases in 
evolution of murine lupus nephritis
Recently, we demonstrated that anti-DNA antibodies, 
renal DNaseI and matrix MMP mRNA levels and enzyme 
activities are cooperative and instrumental in early and 
late events in murine lupus nephritis, as determined in 
(NZBxNZW)F1 mice [47]. Early phases of nephritis were 
associated with chromatin–IgG complex deposition in 
the mesangial matrix, which correlated with appearance 
of anti-dsDNA antibodies. Subsequent to this event, we 
observed a dramatic downregulation of renal DNaseI 
mRNA level and enzyme activity, while MMP2 and 
MMP9 mRNA levels and enzyme activities increased. 
Reduced levels of renal DNaseI correlated with deﬁ  cient 
renal fragmentation of chromatin from dead cells, and 
with accumulation of large chromatin fragments in 
GBMs. A similar downregulation of DNaseI was not 
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the context of Wegener’s granulomatosis [48]. In situ 
deposi  tion of chromatin fragments has been described in 
several experimental nuclease deﬁ  ciencies on nonauto-
immune backgrounds (reviewed in [49]).
In contrast to the correlation of renal DNaseI shut-
down, Martinez-Valle and colleagues did not observe any 
statistical relationship between serum DNaseI activity 
and disease evolution time, clinical and laboratory 
parameters including proteinuria and autoantibodies, or 
the treatment pattern received by the patients [50,51]. In 
agreement with this observation, increasing DNaseI 
activity in vivo by injecting recombinant human DNaseI 
intravenously and subcutaneously in patients with SLE 
failed to show any eﬀ  ect on serum markers of disease 
activity [52]. Furthermore, mutations causing reduced 
DNaseI in lupus patients did not correlate with unique 
clinical symp  toms [53]. Th   is lack of correlation may mean 
that extracellular DNaseI enzyme activity is not 
important in the context of lupus nephritis pathogenesis. 
Rather, DNaseI is important in the context of cell death, 
where DNaseI is in fact the initiator of chromatin 
fragmentation in order to fascili  tate a silent removal to 
avoid, for example, inﬂ  ammation [54,55]. Renal DNaseI 
gene shutdown may therefore impose chromatin expo-
sure in situ because of ineﬃ   cient enzymatic degradation. 
In this model, serum DNaseI may play an inferior role in 
extracellular chromatin degrada  tion. It is questionable 
whether extracellular chromatin, when bound to mem-
branes and covered by IgGs, will be degraded at all by 
DNaseI.
Recent data in murine lupus nephritis thus demonstrate 
that acquired loss of renal DNaseI enzyme activity is a 
dominant event responsible for the progression of 
mesangial nephritis into end-stage organ disease [47]. 
However, exposed chromatin may not be pathogenic in 
the absence of antibodies to dsDNA or to nucleosomes 
[56]. Th  e principal cellular and molecular requirements 
needed to produce these autoantibodies have been 
explained experimentally [35-38], but the mechanism(s) 
accounting for them in vivo in the context of SLE and 
lupus nephritis has not yet been determined. Published 
data, however, indicate that defects in nucleases linked to 
apoptotic or necrotic cell death are not associated with 
induction of anti-dsDNA or anti-nucleosome autoanti-
bodies (for review, see [49]). Th  e data discussed here, 
nevertheless, explain how an unusual exposure of chro-
matin may be a central factor in the evolution of lupus 
nephritis, but not in promoting nephritogenic chromatin-
speciﬁ  c autoimmunity.
Since chromatin fragments stimulate TLRs in, for 
example, dendritic cells [57], this may also explain 
increased expression of MMPs in lupus nephritic kidneys 
[58].
With loss of renal DNaseI, the signalling pathway from 
chromatin fragment-stimulation of TLR to MMP expres-
sion has been described [58,59]. MMPs are collagenases 
with potential to disintegrate membranes [32,33]. 
Membrane disintegration may promote deposition of 
immune complexes in GBMs.
Chromatin in murine lupus nephritis: inducer and 
target for anti-DNA antibodies
In murine lupus nephritis, anti-DNA antibodies gain 
their pathogenic potential when chromatin fragments are 
exposed in glomeruli. Chromatin fragments thus repre-
sent the axis in a circulus vitiosus, where chromatin – the 
inducer of nephritogenic autoimmunity – is the glomeru-
lar target for the autoantibodies, and thereby accounts 
for the organ disease (discussed in [60,61]).
Chromatin fragments exposed in the kidneys may 
derive from either increased apoptosis or deﬁ  cient clear-
ance of apoptotic or secondary necrotic material [61-63]. 
How tolerance against chromatin components is termi-
nated is not fully understood. Chromatin undergoes 
alterations during apoptosis and is normally not exposed 
for the immune system. In the case of increased apoptosis 
or deﬁ  cient clearance, however, these components may 
be exposed as secondary necrotic chromatin with the 
potential to induce an antigen-selective immune res  ponse 
[64-66]. For example, plasma chromatin found in SLE 
patients is hypomethylated [66], and hypomethylated 
DNA is more immunogenic and can induce maturation 
of dendritic cells and potentially activate autoimmune T 
cells and B cells [67]. Further  more, sera of SLE patients 
contain circulating chromatin fragments complexed with 
the DNA-binding protein HMGB1 [61]. Th   is protein is a 
proinﬂ   ammatory mediator that binds chromatin of 
apoptotic cells. Th  e HMGB1–nucleosome complexes 
may activate antigen-presenting cells, which have the 
potential to promote activa  tion of relevant T-helper cells 
and then DNA-speciﬁ   c B cells, with production of 
chromatin-speciﬁ   c autoantibodies as a net result [61]. 
Exposed and retained chromatin may therefore promote 
production of chromatin-speciﬁ  c autoantibodies.
In an infectious context, viruses such as polyomavirus 
BK may induce cell death as a consequence of virus repli-
cation. Th  is process may be relevant to lupus nephritis, 
since there are several reports that demonstrate produc-
tive polyomavirus infection in human SLE (see [35] and 
references therein). Productive renal polyoma virus 
activation may be imposed by treatment of the disease 
with immuno  suppressive drugs, and may not be 
speciﬁ  cally linked to the lupus pathogenesis [68,69]. Th  is 
expression pattern is similar to what is seen in renal 
transplants during immuno  suppresion [70,71].
Irrespective of the cause for polyomavirus replication, 
the viral transcription factor large T antigen forms 
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may aﬀ  ect the immune system in analogy with a hapten–
carrier complex, where B cells bind nucleosomal DNA 
(the hapten) through the DNA-speciﬁ  c antigen receptor 
and process and present T-antigen-derived peptides (the 
carrier) to nontolerant T cells (this model is extensively 
reviewed in [35]). Chromatin may thus generate auto-
immunity by quite diﬀ  erent pathways linked to modiﬁ  ca-
tion of chromatin and various infections [36,72].
We recently performed in vitro studies demonstrating 
that nucleosomes and nucleosomes in complex with anti-
DNA antibodies have high aﬃ   nity for glomerular and 
epidermal basement membrane components such as 
laminin and collagen [73]. Th  is aﬃ   nity may be a major 
factor that explains why chromatin-containing immune 
complexes associate with membrane and matrix struc-
tures in human nephritis [47].
One factor that may contribute to deviation in 
chromatin composition and size is DNaseI, which is the 
major nuclease in kidneys [21] but also in serum, where it 
may participate in chromatin degradation in context of 
necrosis [55,74]. Several studies have demonstrated 
reduced levels of serum DNaseI in SLE patients [50,51, 
74-76]. Th  is reduction could provisionally explain why 
the chromatin concentration in circulation of lupus 
patients with nephritis is reported to be higher than in 
control individuals [77,78]. Another reason for this 
reduction could be that immune complexes in SLE 
patients are protected against nuclease attacks by DNA-
binding proteins and immunoglobulins, present in sera. 
A problem that needs to be solved is therefore whether 
circulating chromatin-containing immune complexes in 
lupus nephritis patients are less sensitive to DNaseI than 
chromatin fragments in anti-chromatin antibody-
negative healthy donors.
Most of the data on lupus nephritis so far relate to 
studies of murine models of the disease. In the next sec-
tion, we will translate available basic data into a detailed 
evidence-based model for human lupus nephritis. We 
shall subsequently convert this information into new and 
rational treatment modalities.
Human lupus nephritis
Irrespective of the complexity of potentially nephrito-
genic autoantibodies associated with SLE, a consensus 
has evolved that antibodies to dsDNA and nucleosomes 
are central pathogenic factors involved in development of 
human lupus nephritis [12,23,24,79-81]. Th  e divergent 
models to explain the basic processes in human lupus 
nephritis may have evolved simply because we still lack 
data that provide deﬁ   nitive insight into the nephritic 
process(es).
In a pilot study, data demonstrate that human nephrito-
genic anti-DNA antibodies bind chromatin-like structures 
in GBMs and the mesangial matrix [82], similar to what 
we have observed in murine lupus nephritis [47]. In that 
pilot study it became evident that in-vivo-bound GBM-
associated autoantibodies co-localised in electron-dense 
structures with experimental antibodies to histone H1, 
histone H3 and transcription factor TBP, and with nicked 
DNA [82]; that is, results identical to those observed in 
murine lupus nephritis. In a recent study, we also demon-
strated in advanced stages of human lupus nephritis that 
the DNaseI protein was nearly absent in the nephritic 
kidneys compared with non-nephritic kidneys and 
nonaﬀ  ected tissue of kidneys extirpated due to cancer 
[48]. Th   e nephritic processes such as those determined in 
murine lupus nephritis thus seem highly relevant to 
understand the process in the human form of the disease. 
Th  e disease process as outlined in Figure 1 is therefore 
most probably relevant to understand both forms of 
lupus nephritis.
Based on the results discussed above, we propose the 
following model to understand initiation and progression 
of lupus nephritis in both mice and humans. Th  e data 
from murine lupus nephritis are summarised as follows 
(see Figure 1 for details). Th  e impact of antibodies to 
dsDNA is crucial for early deposition of chromatin frag-
ments in the mesangial matrix. Linked to progression of 
the disease, secondary necrotic chromatin fragments are 
generated and retained in kidneys when the renal nuclease 
DNaseI mRNA level and DNaseI enzyme activity are 
downregulated. Secondary to this process, chromatin is 
not degraded appropriately, and instead large chromatin 
fragments are retained in glomerular capillary membranes 
in association with chromatin-reactive IgG autoantibodies. 
In this situation, chromatin fragments are also exposed to 
macrophages and dendritic cells in which they stimulate 
TLRs, which may explain the increased expression of 
MMPs. Th  e increase of MMPs may further impose 
deposition of chromatin fragments in glomerular 
membranes because of capillary membrane disintegration 
[32-34]. Our conclusion is that human lupus nephritis is 
dependent on the same distinct processes.
Acquired loss of DNaseI in both murine and human 
lupus nephritis may be controlled at diﬀ  erent  levels, 
including activation of convergently encoded genes using 
sequence elements from the DNaseI gene, methylation of 
DNaseI encoding elements and the promoter, or interfer-
ence with miRNA targeting DNaseI mRNA or other 
mRNAs involved in expression of DNaseI. Th  is  hypothe-
sis is currently under investigation in our laboratory.
Potential implications of data on murine lupus 
nephritis for human lupus nephritis with respect to 
new treatment strategies
Despite improvements in outcomes of immuno  suppres-
sive treatment of patients with lupus nephritis, renal 
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2  years; approximately 10% may progress to end-stage 
renal disease [83,84], which is associated with signiﬁ  -
cantly increased rates of cardiovascular mortality [85]. In 
general, patients with SLE and renal involvement have 
more cardiovascular disease than the remaining SLE 
patients [86,87]. Th  ese  ﬁ   ndings call for improved 
treatment regimes for patients with lupus nephritis, not 
only in terms of improved renal outcome but also with 
regard to cardiovascular outcome.
Th  e results discussed above on the aetiology of lupus 
nephritis demonstrate that DNaseI, the major renal 
nuclease, is profoundly downregulated during develop-
ment of severe membrano-proliferative nephritis. Con-
sider  ing this single information, it may be sound to 
conclude that lupus nephritis is a disease entity that 
depends on processes that are unique to the kidney, and 
that an acquired shutdown of renal DNaseI is the factor 
that determines the disease process and clinical outcome, 
as outlined in Figure 1. Th  is opens the way for new 
therapeutic directions
Causal therapy of lupus nephritis: are there 
contours of new tracks in this landscape?
Th   ere are strong data allowing us to assume that the two-
stepped process accounting for murine lupus nephritis is 
also relevant in human lupus nephritis. If this assumption 
is correct then we can introduce new types of treatment 
focusing on disruption of chromatin structures in vivo by 
chaperone molecules that open the compact and 
nuclease/protease-resistant chromatin structure. Such 
molecules may make the chromatin structure more 
susceptible for proteases and nucleases [88-91]. On the 
contrary, certain chaperone molecules may prevent bind-
ing of nucleo  somes to glomerular membranes by altering 
the net charge of chromatin fragments, as demonstrated 
in vitro by surface plasmon resonance [92], and also 
potentially in vivo in the context of permanent infusion 
of such chaperone molecules [92]. Th  erefore, it is 
important to determine whether processes that account 
for the poten  tially fatal human lupus nephritis can be 
avoided without inﬂ  uence on the immune system. In the 
next section, a possible strategy and relevant experiments 
will be discussed.
An approach to new therapeutic principals applied 
to lupus nephritis
One possible approach is to use molecules that are 
involved in chromatin assembly, disassembly or re-
modelling. Such molecules have the ability to alter the 
conformation of the chromatin structure, which may result 
in increased sensitivity for both nucleases and proteases. 
Th   is could lead to increased degradation of the potentially 
immunogenic chromatin fragments [61,93] – fragments 
that otherwise would be presented to the immune system 
– thereby inducing pathogenic anti-dsDNA/anti-nucleo-
some antibody responses.
Th   is idea derives from the described eﬀ  ects  of 
chaperone molecules such as nucleosome assembly 
protein 1, a histone chaperone molecule that modulates 
binding of the linker DNA-associated histone H1 to 
chromatin and induces an extended and open chromatin 
ﬁ   bre conformation [94,95]. Nucleoplasmin is also a 
histone chaperone that binds and exchanges histones to 
re-establish the chromatin structure, and is involved in 
opening and relaxation of the chromatin structures 
[91,96]. Th   e heat shock protein HSP90 has a similar eﬀ  ect 
on chromatin structure [97,98].
Th   ese are examples of molecules that induce changes in 
chromatin conformation which may result in increased 
accessibility for proteases and nucleases and in increased 
degradation of nucleosomes. Whether chaperone mole-
cules are tolerated in vivo in doses necessary for 
therapeutic eﬀ   ect has not been determined. One 
chaperone molecule that may be used in a therapeutic 
context is heparin, a negatively charged molecule that is 
well tolerated in vivo and has similar eﬀ  ects on chromatin 
structure as the molecules mentioned above.  Heparin 
derivatives have been evaluated for their eﬀ  ect  on 
nucleosome and chromatin structure. Common for these 
studies are data demonstrating that heparin makes 
nucleosomes more accessible to nucleases [74,99] by 
binding the trypsin-sensitive solvent-phase tails of the 
core histones [88].  Heparin also increases enhancer–
promoter commu  ni  cation [100] by disassembling the 
chromatin structure [101,102]. Typical for heparin-
induced structural changes is increased fragmentation of 
the nucleosomal structure by nucleases ubiquitously 
present in biological ﬂ  uids [99]. As anionic heparin binds 
tightly to histone tails, and potentially changes the net 
charge of the nucleosome, heparin may in fact also inhibit 
binding of nucleosome-containing immune complexes to 
components of the GBM, like laminins and collagens. 
Heparin may thus have a two-sided eﬀ  ect on the role of 
chromatin frag  ments in lupus nephritis; increased 
enzymatic degrada  tion of chromatin fragments, and 
inhibition of their binding to glomerular membranes.
Heparin derivatives inhibit binding of chromatin 
to glomerular basement membranes and increase 
their enzyme-mediated degradation
Interfering with chromatin–IgG complex binding to 
glomerular extracellular membranes could be a new 
treatment strategy. Negatively charged heparin binds to 
positively charged histones in the nucleosome complex 
and opens their architecture [88].
A pilot study has demonstrated that chromatin is more 
sensitive to both DNaseI and proteases in the presence of 
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chromatin structure. Highly promising was the obser-
vation that heparin inhibited binding of chromatin–IgG 
complexes to glomerular laminin and collagen in vitro, as 
demonstrated by surface plasmon reso  nance (Figure 1) 
[92]. Th  ere is thus a strong indication that heparin 
deriva  tives (or other nucleosome re-modelling proteins 
such as nucleoplasmin [91]) indeed exert a two-sided 
therapeutic eﬀ   ect on lupus nephritis: heparin alters 
chromatin structures and allows a nearby complete 
degradation of B-cell-recognising DNA in chromatin, 
thus preventing production of nephritogenic anti-DNA 
Figure 1. Exposed, extracellular chromatin is a central factor in evolution of lupus nephritis – a model. In normal situations, chromatin is 
eff  ectively removed in the context of apoptosis. When chromatin fragments are not appropriately cleared, they may be exposed in tissue or in 
circulation. Exposure of chromatin may have an impact on the immune system. Chromatin may recirculate as oligonucleosomes, and eventually 
activate dendritic cells (DC). These cells present chromatin-derived peptides and upregulated co-stimulatory molecules to naïve peptide-specifi  c 
CD4+ T cells. Activated T cells may subsequently recirculate and provide help to DNA-specifi  c or nucleosome-specifi  c B cells to be transformed 
into antibody-secreting plasma cells. In this situation the antibodies are potentially pathogenic, but to exert this potential they must bind exposed 
chromatin fragments. This may happen in the kidneys when DNaseI is downregulated, and may have an immense impact on the pathogenic eff  ect 
of the autoantibodies. Chromatin in cells dying from, for example, apoptosis may, due to loss of DNaseI, not be degraded, and instead of clearance 
they become exposed as secondary necrotic chromatin in, for example, glomerular basement membranes (GBMs), where they are targeted by 
induced anti-chromatin antibodies. Chromatin fragments may thus exert two eff  ects with fatal consequences for the kidneys: they may induce 
autoimmunity (nucleosomes), and they represent targets for the induced autoantibodies (chromatin fragments). This identifi  es two hot points for 
therapy with chaperone molecules such as heparin: increased nuclease-mediated digestion of nucleosomal DNA, and thereby reduced load of 
immunogenic DNA; and prevention of binding of immunocomplexes containing chromatin fragments to GBMs and matrices (arrow to the left, 
surface plasmon resonance analysis of the eff  ect of heparin, bottom right). Binding of nucleosomes to laminin was reduced by unfractionated 
heparin reaching approximately 75% and 100% inhibition at a nucleosome:heparin molar ratio of 1:1 and 1:10, respectively. For experimental 
details, see [73]. One single chaperone molecule may thus have a two-sided benefi  cial eff  ect on lupus nephritis. KD, equilibrium dissociation 
constant; PC, plasma cell; TLR, Toll-like receptor; TUNEL IEM, terminal deoxynucleotidyltransferase biotin-dUTP nicked end-labelled immune electron 
microscopy. Modifi  ed with permission from [34], © 2010 Macmillan Publishers Ltd.
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IgG fragments that escape enzymatic degradation in vivo 
[92]. Continuous infusion of heparin delayed production 
of anti-dsDNA antibodies and development of lupus 
nephritis in (NZBxNZW)F1 hybrid mice. Previous 
studies have revealed that heparin/heparinoid treatment 
has a therapeutic eﬀ  ect on the activity of lupus nephritis 
in MRL-lpr/lpr mice [103]. Th  e mechanism(s) for this 
therapeutic eﬀ  ect, however, was not determined – but 
the anticoagulant eﬀ  ect does not seem to be essential 
[103]. In another study, Naparstek and colleagues indi-
cated that the binding of antibodies to dsDNA could be 
inhibited by heparin [104]. Th  is potentially important 
observation, however, has not been followed up by 
further studies.
Th   e aim of current experiments in our laboratory is to 
determine an epigenetic mechanism(s) for renal DNaseI 
shutdown, and to analyse whether DNaseI sensitivity of 
immune complexes puriﬁ   ed from patients with lupus 
nephritis is increased by heparin at concentrations 
tolerated in a clinical context. Highly relevant also are the 
planned experiments to analyse whether low molecular 
weight heparin interferes with processing and presen-
tation of chromatin fragments by antigen-presenting 
cells.
Concluding remarks and perspectives
Detailed studies have oﬀ  ered new insight into molecular 
and transcriptional events that explain processes contri-
buting to lupus nephritis. Th  is insight has provided us 
with new therapeutic ideas and possibilities. Analysing 
chemical compounds that inhibit binding of chromatin–
IgG complexes to components of the extracellular 
matrices and membranes, in combination with alteration 
of extracellular chromatin structure to make them more 
sensitive to proteases and nucleases, is the focus for our 
investigation. In the future it may be possible to prevent 
both autoimmunity to DNA and chromatin fragments on 
one side, and to inhibit binding of chromatin fragments 
to the mesangial matrix and the GBMs on the other side.
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